ClinicalTrials.gg
Active, not recruitingNCT07170319Updated Dec 31, 2025

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

A Phase 1 interventional study of IBI3032 and placebo in Overweight or Obesity, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Obesity by Innovent Biologics, Inc. — 5 open to participants now, 9 under way, 4 of them phase 3. Obesity · Innovent Biologics, Inc..

Enrollment
13th of 16
79 · median 135
Started
2025
with 5 others
Phase 1
6 of 16
2 open now
Registered
12th of 16
by date

Among the 16 studies in Obesity by Innovent Biologics, Inc., this one is the 13th largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 16 studies in Obesity by Innovent Biologics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Obesity by Innovent Biologics, Inc., or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 79 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center) is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or females, as determined by medical history
  • Have safety laboratory results within normal reference ranges

Exclusion criteria

Exclusion Criteria:

  • Have known allergies toIBI3032, glucagon-like peptide-1 (GLP-1) analogs, related compounds
  • Abnormal (ECG) at screening
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Multiple ascending dose5 of IBI3032 administered orally.

    Cohort 5 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Multiple ascending dose1 of placebo administered orally.

    Cohort 1 placebo

    Drug: placebo

  • Placebo comparator
    Multiple ascending dose4 of placebo administered orally.

    Cohort 4 placebo

    Drug: placebo

  • Experimental
    Multiple ascending dose3 of IBI3032 administered orally.

    Cohort 3 IBI3032

    Drug: IBI3032

  • Experimental
    Multiple ascending dose4 of IBI3032 administered orally.

    Cohort 4 IBI3032

    Drug: IBI3032

  • Experimental
    Multiple ascending dose2 of IBI3032 administered orally.

    Cohort 2 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Multiple ascending dose3 of placebo administered orally.

    Cohort 3 placebo

    Drug: placebo

  • Placebo comparator
    Multiple ascending dose5 of placebo administered orally.

    Cohort 5 placebo

    Drug: placebo

  • Experimental
    Multiple ascending dose1 of IBI3032 administered orally.

    Cohort 1 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Multiple ascending dose2 of placebo administered orally.

    Cohort 2 placebo

    Drug: placebo

Interventions

  • IBI3032. Method of administration: oral, fasted administration.

  • Drugplacebo

    Placebo (without active ingredients). Method of administration: oral, fasted administration.

07

What researchers measure

Primary outcomes

  1. Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Day 43

  2. Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Day 43

  3. Number of Participants with adverse events (AEs)

    Baseline up to Day 43

    Time frame: An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Secondary outcomes

  1. Under the Serum Concentration-time Curve (AUC) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Day 1 and Day 28:Predose up to 24 hours postdose. Day 8, Day 15 and Day 22:Predose up to 4 hours postdose.

  2. maximum concentration (Cmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Day 1 and Day 28:Predose up to 24 hours postdose. Day 8, Day 15 and Day 22:Predose up to 4 hours postdose.

  3. time to maximum concentration (Tmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Day 1 and Day 28:Predose up to 24 hours postdose. Day 8, Day 15 and Day 22:Predose up to 4 hours postdose.

  4. clearance (CL) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Day 1 and Day 28:Predose up to 24 hours postdose. Day 8, Day 15 and Day 22:Predose up to 4 hours postdose.

  5. apparent volume of distribution (V) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Day 1 and Day 28:Predose up to 24 hours postdose. Day 8, Day 15 and Day 22:Predose up to 4 hours postdose.

  6. elimination half-life (T1/2) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Day 1 and Day 28:Predose up to 24 hours postdose. Day 8, Day 15 and Day 22:Predose up to 4 hours postdose.

08

Study locations

1 site
  • The Frist Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Dec 2025, 2 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 2 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 12, 2025
StartActual
Sep 25, 2025
Primary completionActual
Dec 24, 2025
CompletionEst.
Mar 31, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07170319
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 25, 2025
Primary completion
Dec 24, 2025
Completion
Mar 31, 2026 (estimated)
Last update
Dec 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3032

Start the discussion